N/A N=166 Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
Herpes Zoster
Primary: Answers to Survey Questions — 89; 71.2; 98; 74 Percentage of responders
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Closed Loop Propofol Administration in Pediatric Cardiac Surgery
Pediatric Cardiac Surgery · Intraoperative Awareness · Automated Drug Delivery
Primary: Percentage of Time Bispectral Index(BIS) Remains+/-10 of Target — 77.4; 75 percentage of time
Phase 2 N=52 Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
Acute Coronary Syndrome
Primary: Change From Baseline in Plaque Imaging After 24 Weeks — -0.01; -0.06 TBR — p=0.34
Phase 3 N=279 A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84) — -0.859; -1.118 meters per second (m/sec)…
Phase 3 N=243 A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
Asthma
Primary: Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) — 4; 7; 1; 52 Participants
Phase 1 N=13 Campath in Chronic GVHD
Chronic Graft-vs.-Host Disease
Primary: The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids — 53 mg
Phase 2 N=40 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response — 10 Participants
Phase 3 N=22 The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence
Alcoholism · Sleep Initiation and Maintenance Disorders
Primary: Sleep Efficiency (From an In-laboratory Polysomnogram) — 70.70; 78.63; 79.45; 82.80 percentage — p=0.49
Phase 2 N=26 A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function
Asthma
Primary: Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0-24 Hours Post-dose on Day 14 — 2.811; 3.188; 3.233 Liters
Phase 2 N=26 Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
Asthma
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 4; 1; 0; 0 Participants
Phase 2 N=27 Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
Asthma
Primary: Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of…
Phase 3 N=523 QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12 — 1.69; 1.56 liters
Phase 2 N=17 GM-CSF in Treating Patients With Relapsed Prostate Cancer
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response — 2; 0 participants
Phase 3 N=394 BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Colon Cancer
Primary: Efficacy - Preparation Quality Using a 4 Point Scale — 90; 84 percentage of participants
N/A N=192 Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
Seizures
Primary: Mean Total Daily Dose of VIMPAT® (mg) at Baseline — 272.1 mg/day of Vimpat